Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**TP-ICG** is an investigational Trop2-targeted near-infrared-II fluorescent molecular imaging probe composed of a Trop2-targeting polypeptide linked to indocyanine green. It is designed to bind trophoblast cell surface antigen 2-expressing ovarian cancer cells and provide intraoperative fluorescence visualization of tumor margins and small abdominal metastatic lesions during cytoreductive surgery. In cell and mouse models of Trop2-positive ovarian cancer, TP-ICG showed higher tumor uptake and tumor-to-background signal than a control probe and detected metastatic lesions smaller than 1 mm. ([aacrjournals.org](https://aacrjournals.org/cancerres/article/85/8_Supplement_2/LB479/761606/Abstract-LB479-Nir-ii-fluorescence-imaging-based))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TP-ICG.